| Revision as of 02:36, 3 November 2005 edit207.210.15.85 (talk)No edit summary← Previous edit | Revision as of 19:39, 6 November 2005 edit undo61.246.151.234 (talk) →External linksNext edit → | ||
| Line 46: | Line 46: | ||
| ==External links== | ==External links== | ||
| * | * | ||
| * | |||
| * - medlineplus.org | * - medlineplus.org | ||
| * | * | ||
Revision as of 19:39, 6 November 2005
|
| |
| IUPAC chemical name | |
| CAS number ? |
ATC code ? |
| Chemical formula | C18H19NOS, HCl |
| Molecular weight | 333.38 |
| Bioavailability | ? |
| Metabolism | Hepatic Oxidation |
| Elimination half-life | 8-17 hours |
| Excretion | 70% in urine, 20% in feces |
| Pregnancy category | C (USA) |
| Legal status | Prescription only (USA) |
| Routes of administration | Oral |
Duloxetine hydrochloride (brand names: Cymbalta/Yentreve) is a medically used drug that primarily targets major depressive disorders (MDD), pain related to diabetic peripheral neuropathy and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(S)-N-methyl-3-(1-naphthyloxy)-2-thiophenepropanamine, it is a potent dual inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors.
Furthermore, duloxentine lacks affinity for monoamine receptors within the central nervous system. While there is limited data available regarding the pharmacokinetic profile of duloxetine in humans, its half-life is reported to be 10 to 15 hours.
Duloxentine is also approved by the FDA for the treatment of diabetic neuropathy.
External links
- Manufacturer website
- Duloxetine - medlineplus.org
- Mediacation Guide
- Prescribing Guide
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |